140 related articles for article (PubMed ID: 37192745)
1. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
[TBL] [Abstract][Full Text] [Related]
2. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
3. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
4. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
5. tRNA-Derived RNA Fragments Are Novel Biomarkers for Diagnosis, Prognosis, and Tumor Subtypes in Prostate Cancer.
Liu W; Yu M; Cheng S; Zhou X; Li J; Lu Y; Liu P; Ding S
Curr Oncol; 2023 Jan; 30(1):981-999. PubMed ID: 36661724
[TBL] [Abstract][Full Text] [Related]
6. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
[TBL] [Abstract][Full Text] [Related]
8. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
9. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract][Full Text] [Related]
10. Myelin and lymphocyte protein 2 regulates cell proliferation and metastasis through the Notch pathway in prostate adenocarcinoma.
Zheng C; Wang J; Zhang J; Hou S; Zheng Y; Wang Q
Transl Androl Urol; 2021 May; 10(5):2067-2077. PubMed ID: 34159087
[TBL] [Abstract][Full Text] [Related]
11. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
12. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
13. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
14. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
15. Identification of prostate cancer specific methylation biomarkers from a multi-cancer analysis.
Pu Y; Li C; Yuan H; Wang X
BMC Bioinformatics; 2021 Oct; 22(1):492. PubMed ID: 34641790
[TBL] [Abstract][Full Text] [Related]
16. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's Disease as a Risk Factor for Prostate Adenocarcinoma: A Molecular Point of View.
Liu T; Yang Z; Liu S; Wei J
Gerontology; 2023; 69(8):986-1001. PubMed ID: 36921580
[TBL] [Abstract][Full Text] [Related]
19. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
